
First circular RNA begins trials in radiation-induced xerostomia
RiboX Therapeutics has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation. RXRG001 is the first circular RNA therapy to receive FDA IND clearance. Xerostomia and hyposalivation… Read More















